

### REMARKS

In the response filed February 25, 2009, Applicants pointed out that the claimed compound (i.e., methanesulfonate salt form) exhibits unexpectedly superior thermal stability over the hydrochloride salt form. Applicants also explained that the effect is specific to the methanesulfonate salt because the thermal stability cannot be obtained by other pharmaceutically acceptable salts. For example, the phosphoric acid salt of 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine has endothermic and exothermic peaks and has a problem in thermal stability (page 13, lines 6-10).

In order to support these statements, submitted herewith is a Declaration under 37 C.F.R. § 1.132. In the Declaration, the Declarant compared the thermal stability of the phosphoric acid salt form to the thermal stability of the claimed methanesulfonate salt form via Differential Scanning Calorimeter (DSC) assay.

The results in the Declaration show that the phosphoric acid salt of 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine (Figure 1) exhibits thermal instability, as evidenced by the presence of endothermic and exothermic peaks, whereas the claimed methanesulfonate salt form (Figure 2) exhibits superior thermal stability over a wide range of temperatures.

Accordingly, the Differential Scanning Calorimeter(DSC) data in the Declaration demonstrates that the methanesulfonate form claimed in the present invention exhibits unexpectedly superior properties over other salt forms.


In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 and Submission of Executed Declaration under 37 C.F.R. § 1.132 Attorney Docket No.: Q92149  
Application No.: 10/561,214

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

  
Susan J. Mack  
Registration No. 30,951

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

**65565**

CUSTOMER NUMBER

Date: March 16, 2009